Table 1 Demographic and clinicopathological characteristics of pancreatic cancer patients diagnosed with iIPMN, iMCN, iSPN, and iSCN
Variables | iIPMN (N = 6836) (N, %) | iMCN (N = 504) (N, %) | iSPN (N = 418) (N, %) | iSCN (N = 19) (N, %) | SUM (N = 7777) (N, %) |
|---|---|---|---|---|---|
Age | < 0.001 | ||||
< 56 | 1007 (14.7) | 137 (27.2) | 364 (87.1) | 2 (10.5) | 1510 (19.4) |
56–75 | 3793 (55.5) | 194 (38.5) | 49 (11.7) | 13 (68.4) | 4049 (52.1) |
> 75 | 2036 (29.8) | 173 (34.3) | 5 (1.2) | 4 (21.1) | 2218 (28.5) |
Sex | < 0.001 | ||||
Female | 3495 (51.1) | 352 (69.8) | 355 (84.9) | 15 (78.9) | 4217 (54.2) |
Male | 3341 (48.9) | 152 (30.2) | 63 (15.1) | 4 (21.1) | 3560 (45.8) |
Race | < 0.001 | ||||
White | 5562 (81.4) | 395 (78.4) | 284 (67.9) | 15 (78.9) | 6256 (80.4) |
Black | 745 (10.9) | 61 (12.1) | 78 (18.7) | 2 (10.5) | 886 (11.4) |
Asian-Pacific | 510 (7.5) | 46 (9.1) | 52 (12.4) | 2 (10.5) | 610 (7.8) |
Unknown | 19 (0.3) | 2 (0.4) | 4 (0.1) | 0 (0) | 29 (0.3) |
Year of diagnosis | < 0.001 | ||||
2000–2008 | 3562 (52.1) | 350 (69.4) | 78 (18.7) | 10 (52.6) | 4000 (51.4) |
2009–2018 | 3274 (47.9) | 154 (30.6) | 340 (81.3) | 9 (47.4) | 3777 (48.6) |
Primary site | < 0.001 | ||||
Head | 3002 (43.9) | 131 (26.0) | 115 (27.5) | 6 (31.6) | 3254 (41.8) |
Body | 790 (11.6) | 65 (12.9) | 70 (16.7) | 1 (5.3) | 926 (11.9) |
Tail | 1049 (15.3) | 174 (34.5) | 160 (38.3) | 7 (36.8) | 1390 (17.9) |
others | 1995 (29.2) | 134 (26.6) | 73 (17.5) | 5 (26.3) | 2207 (28.4) |
Pathological grade | < 0.001 | ||||
I | 686 (10.0) | 69 (13.7) | 66 (15.8) | 4 (21.1) | 825 (10.6) |
II | 1212 (17.7) | 91 (18.1) | 25 (6.0) | 1 (5.3) | 1329 (17.1) |
III–IV | 737 (10.8) | 49 (9.7) | 3 (0.7) | 1 (5.3) | 790 (10.2) |
Unknown | 4201 (61.5) | 295 (58.5) | 324 (77.5) | 13 (68.4) | 4833 (62.1) |
Regional nodes examined | < 0.001 | ||||
0–7 | 5436 (79.5) | 373 (74.0) | 225 (53.8) | 15 (78.9) | 6049 (77.8) |
8–14 | 443 (6.5) | 60 (11.9) | 100 (23.9) | 1 (5.3) | 604 (7.8) |
> 14 | 626 (9.2) | 51 (10.1) | 80 (19.1) | 2 (10.5) | 759 (9.8) |
Unknown | 331 (4.8) | 20 (4.0) | 13 (3.1) | 1 (5.3) | 365 (4.7) |
T stage | < 0.001 | ||||
T1 | 504 (7.4) | 48 (9.5) | 43 (10.3) | 0 (0.0) | 595 (7.7) |
T2 | 1418 (20.7) | 67 (13.3) | 113 (27.0) | 1 (5.3) | 1599 (20.6) |
T3 | 1309 (19.1) | 201 (40.0) | 215 (51.4) | 10 (52.6) | 1735 (22.3) |
T4 | 967 (14.1) | 46 (9.1) | 9 (2.2) | 3 (15.8) | 1025 (13.2) |
Tx | 3605 (52.7) | 142 (28.2) | 38 (9.1) | 5 (26.3) | 3790 (48.7) |
N stage | < 0.001 | ||||
N0 | 1086 (15.9) | 190 (37.7) | 303 (72.5) | 6 (31.6) | 1585 (20.4) |
N1 | 545 (8.0) | 44 (8.7) | 17 (4.1) | 2 (10.5) | 608 (7.8) |
N2 | 213 (3.1) | 15 (3.0) | 1 (0.2) | 0 (0.0) | 229 (2.9) |
Nx | 4992 (73.0) | 255 (50.6) | 97 (23.2) | 11 (57.9) | 5355 (68.9) |
M stage | < 0.001 | ||||
M0 | 2824 (41.3) | 354 (70.2) | 381 (91.1) | 9 (47.4) | 3568 (45.9) |
M1 | 3689 (54.0) | 106 (21.0) | 27 (6.5) | 9 (47.4) | 3831 (49.3) |
Mx | 323 (4.7) | 44 (8.7) | 10 (2.4) | 1 (5.3) | 378 (4.9) |
TNM stage | < 0.001 | ||||
IA | 238 (3.5) | 31 (6.2) | 37 (8.9) | 0 (0.0) | 306 (3.9) |
IB | 264 (3.7) | 32 (6.3) | 88 (21.1) | 1 (5.3) | 385 (5.0) |
IIA | 261 (3.8) | 90 (17.9) | 159 (38.0) | 2 (10.5) | 512 (6.6) |
IIB | 334 (4.9) | 31 (6.2) | 13 (3.1) | 2 (10.5) | 380 (4.9) |
III | 611 (8.9) | 37 (7.3) | 5 (1.2) | 1 (5.3) | 654 (8.4) |
IV | 3689 (54.0) | 106 (21.0) | 27 (6.5) | 9 (47.4) | 3831 (49.3) |
Unknown | 1439 (21.1) | 177 (35.1) | 89 (21.3) | 4 (21.1) | 1709 (22.0) |
Surgery | < 0.001 | ||||
Yes | 1653 (23.9) | 283 (56.1) | 366 (87.5) | 10 (52.6) | 2312 (29.7) |
No/unknown | 5183 (76.1) | 221 (43.9) | 52 (12.5) | 9 (47.4) | 5465 (70.3) |
Radiotherapy | < 0.001 | ||||
Yes | 1012 (14.8) | 81 (16.1) | 8 (1.9) | 3 (15.8) | 1104 (14.2) |
No/unknown | 5824 (85.2) | 423 (83.9) | 410 (98.1) | 16 (84.2) | 6673 (85.8) |
Chemotherapy | < 0.001 | ||||
Yes | 3337 (48.8) | 155 (30.8) | 25 (6.0) | 6 (31.6) | 3523 (45.3) |
No/unknown | 3499 (51.2) | 349 (69.2) | 393 (94.0) | 13 (68.4) | 4254 (54.7) |